Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Infections, Meningococcal Clinical Trial

Official title:

Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00291343
• Other study ID #: 105239 (mth24-30)
• Secondary ID: 105245
• Status: Completed
• Phase: Phase 3
• Start date: February 1, 2006
• Est. completion date: March 15, 2007

Study information

• Verified date: April 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be conducted in three stages. In the DTP booster stage at 15 to 24 months of age, all subjects will receive a booster dose of Tritanrix™-HepB/Hiberix™. In the Mencevax™ ACWY "full dose" stage at 24 to 30 months of age all subjects will receive a dose of Mencevax™ ACWY. In the Mencevax™ ACWY "small dose" stage at 30 to 36 months of age, the first 75 subjects in each of the two centers will be tested for boostability of the MenA and MenC immune response by giving a fifth of a dose of a Mencevax™ ACWY vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Description:

Subjects in the group that was previously primed with Tritanrix™-HepB/Hiberix™ will be the control group for the group that was previously primed with Tritanrix™-HepB/Hib-MenAC.

Blood samples will be drawn from subjects as follows:

• prior to and one month after the full dose of the Mencevax™ ACWY vaccine.

• prior to and one month after 1/5th of a dose of Mencevax™ ACWY vaccine (only for the first 75 subjects in each of the two centers).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 296
• Est. completion date: March 15, 2007
• Est. primary completion date: March 15, 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Months to 24 Months

Eligibility

Inclusion criteria:

• Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.

• A male or female between, and including, 15 and 24 months of age at the time of vaccination.

• Written informed consent obtained from the parent or guardian of the subject.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

• Having participated in the primary vaccination study DTPW-HBV=HIB-MENAC-TT-011 (eTrack No. 100478) in Center No. 4328 or Center No.4329.

Exclusion criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the vaccination, or planned use during the study period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.

• Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of vaccination; with the exception of oral poliovirus vaccine (OPV).

• Booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib) and/or meningococcal serogroups A and/or C disease, after the date of the study conclusion visit of the primary vaccination study DTPW-HBV=HIB-MENAC-TT-011 (eTrack No. 100478).

• History of diphtheria, tetanus, pertussis, hepatitis B, Hib and/or meningococcal serogroup A or C disease.

• Known exposure to diphtheria, tetanus, pertussis, hepatitis B, Hib and/or meningococcal serogroup A or C disease.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

• A family history of congenital or hereditary immunodeficiency.

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

• Major congenital defects or serious chronic illness.

• History of any neurologic disorders or seizures including febrile seizures in infancy.

• Acute disease at the time of enrolment.

• Planned or actual administration of immunoglobulins and/or any blood products within the three months preceding Mencevax™ ACWY vaccination.

Related Conditions & MeSH terms

• Infections, Meningococcal
• Meningococcal Infections

Intervention

Biological:
• Tritanrix™- HepB
One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
• Hiberix™
One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
• Mencevax™ ACWY
One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months

Locations

Country	Name	City	State
Philippines	GSK Investigational Site	Manila
Philippines	GSK Investigational Site	Sampaloc, Manila

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Philippines, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Serum Bactericidal Activity Against Neisseria Meningitidis Serogroups A, C (rSBA-MenA, C) Using Rabbit Complement Antibodies	Antibody cut-offs were higher than or equal to (=) 1:128	1 month after Mencevax ACWY vaccination (at 25 to 31 months of age).
Secondary	Number of Subjects With Anti-rSBA-MenA, C Antibody Titers = Pre-defined Cut-off Values	Pre-defined cut-offs were = 1:8 and = 1:128	Prior to (at 24 to 30 months of age) and after (at 25 to 31 months of age) Mencevax ACWY vaccination.
Secondary	Anti-rSBA-MenA, C Antibody Titers	Antibody titers were expressed as Geometric Mean Titers (GMTs)	Prior to (at 24 to 30 months of age) and after (at 25 to 31 months of age) Mencevax ACWY vaccination.
Secondary	Number of Subjects With Anti-pilysaccharide A and C (Anti-PSA/PSC) Antibody Concentrations = Predefined Cut-off Values	Antibody cut-offs were = 0.3, 2 micrograms per millilitre (µg/mL).	Prior to (at 24 to 30 months of age) and after (at 25 to 31 months of age) Mencevax ACWY vaccination.
Secondary	Anti-PSA, Anti-PSC Antibody Concentrations	Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs).	Prior to (at 24 to 30 months of age) and after (at 25 to 31 months of age) Mencevax ACWY vaccination.
Secondary	Number of Subjects With Anti-hepatitis B Surface (Anti-HBs) Antigen Antibody Concentrations = Cut-offs	The antibody concentrations cut-off was = 10 milli international units per millilitre (mIU/mL).	Prior to the Mencevax ACWY vaccination at 24-30 Months of age
Secondary	Anti-HBs Concentrations	Antibody concnetrations were expressed as Geometric Mean Concentrations (GMCs).	Prior to the Mencevax ACWY vaccination at 24-30 Months of age
Secondary	Number of Subjects With Vaccine Response for rSBA-Men A, C	Vaccine response was defined as follows: for initially seronegative subjects (i.e. with rSBA titer < 1:8 pre-vaccination), rSBA titer = 1:32 post-vaccination (seroconversion), and for initially seropositive subjects (i.e. with rSBA > 1:8 prevaccination), at least a 4-fold increase in rSBA titer from pre-vaccination to post-vaccination.	1 month after Mencevax ACWY vaccination (at 25 to 31 months of age).
Secondary	Number of Subjects With Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness, swelling. Any = symptom occurring regardless of intensity grade.	During the 4-day follow-up period after the Mencevax ACWY vaccination, at 24-30 months of age
Secondary	Number of Subjects With Solicited General Symptoms	Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, rectal fever [= 38 degrees Celsius (°C)]. Any = occurrence of symptom regardless of intensity grade.	During the 4-day follow-up period after the Mencevax ACWY vaccination, at 24-30 months of age
Secondary	Number of Subjects With Unsolicited Adverse Events (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regard-less of intensity grade or relation to vaccination.	From Day 0 at months 15-24 of age to study end at Months 25-31 of age
Secondary	Number of Subjects With Serious Adverse Events (SAEs)	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	From 15-24 Months of age up to Months 25-31 of age

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.